CytomX, which develops antibodies, previously raised $5m in its series A from angels, according to news provider VentureWire.
Switzerland-based healthcare company Roche’s corporate venturing unit has helped CytomX Therapeutics, an antibody development company, raise a further $11m by extending its series B round.
Roche Venture Fund was joined in CytomX’s B round extension, which increased from $30m raised in September 2010, by venture capital firms Canaan Partners, which led the round, and Third Rock Ventures.
Tim Shannon, managing director of Canaan Partners, will join CytomX’s board.
CytomX, which develops antibodies (pictured), previously raised $5m in its series A…
